Focused On-demand Library for SCY1-like protein 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

Coated vesicle-associated kinase of 104 kDa

Alternative UPACC:

Q6P3W7; A8KAB5; Q96EF4; Q96ST4; Q9H7V5; Q9NVH3; Q9P2I7


SCY1-like protein 2, also known as the Coated vesicle-associated kinase of 104 kDa, plays a pivotal role in cellular processes. It is involved in the AP2-containing clathrin coat regulation, crucial for clathrin-dependent trafficking at the plasma membrane, TGN, and endosomal system. Additionally, it potentially acts as a serine/threonine-protein kinase, influencing the beta2-subunit of the plasma membrane adapter complex AP2 and other proteins. Its role in regulating excitatory receptors at synapses underscores its importance in neuronal function, signaling, and brain development.

Therapeutic significance:

SCY1-like protein 2's involvement in Arthrogryposis multiplex congenita 4, a severe developmental condition, highlights its therapeutic significance. Understanding its role could pave the way for innovative treatments for this and potentially other neurological disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.